苯巴比妥与地西泮治疗酒精戒断综合征的比较有效性研究
主要有效性终点显示两组住院时长无差异(边际均值4.1 vs 4.3天,边际均值差-0.21天,95%CI -0.42至0.00天)。主要安全性终点显示两组有创机械通气使用率无差异(边际风险3.1% vs 2.7%,边际风险差0.4%,95%CI -0.7%至1.4%)。次要终点中仅自行出院率有差异,地西泮组更高(9.5% vs 12.6%,边际风险差-3.1%,95%CI -4.9%至-1.3%)。研究提示苯巴比妥与长效苯二氮䓬类药物可能近似等效。
要点
- 入院当日启用苯巴比妥或地西泮治疗酒精戒断综合征,住院时长无差异(边际均值4.1 vs 4.3天,边际均值差-0.21天,95%CI -0.42至0.00天)
- 两组有创机械通气使用率无差异(苯巴比妥3.1% vs 地西泮2.7%,边际风险差0.4%,95%CI -0.7%至1.4%),提示安全性相当
- 地西泮组自行出院率更高(12.6% vs 苯巴比妥9.5%,边际风险差-3.1%,95%CI -4.9%至-1.3%),可能影响治疗依从性
适用人群与场景
- 入院时即有酒精戒断综合征主要诊断的成年住院患者
- 中位年龄45岁(IQR 35-56岁),75.1%为男性
- 在入院当日启用苯巴比妥或地西泮治疗的患者
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 入院当日启用苯巴比妥或地西泮作为酒精戒断综合征的初始治疗药物(具体剂量、途径、频次原文未提及)
- 两种药物在治疗升级需求、严重酒精戒断并发症发生率和资源利用方面无差异
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要有效性终点:住院时长无差异,边际均值4.1 vs 4.3天,边际均值差-0.21天(95%CI -0.42至0.00天)
- 主要安全性终点:有创机械通气使用率无差异,边际风险3.1% vs 2.7%,边际风险差0.4%(95%CI -0.7%至1.4%)
- 次要终点中仅自行出院率有差异,地西泮组更高,边际风险12.6% vs 9.5%,边际风险差-3.1%(95%CI -4.9%至-1.3%)
- 其他次要终点(治疗升级、严重酒精戒断并发症、资源利用)两组无差异
证据类型、等级与局限
- 证据类型:多中心观察性比较有效性研究,采用目标最大似然估计和集成机器学习方法模拟临床试验
- 数据来源:Premier Healthcare Database真实世界数据库
- 局限性:观察性研究设计,非随机对照试验;原文未报告具体药物剂量、给药途径和频次
对床旁实践的改变
- 在酒精戒断综合征住院患者中,苯巴比妥可作为地西泮的替代选择,两者在有效性和安全性方面近似等效
- 选择地西泮时需注意患者自行出院率可能更高(12.6% vs 9.5%),可能影响治疗完整性和随访
- 两种药物在预防严重戒断并发症(如需要有创机械通气)方面效果相当,可根据药物可及性、患者特点和机构经验选择
- 研究结果支持苯巴比妥作为长效苯二氮䓬类药物的合理替代,但需注意原文未提供具体剂量方案
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Phenobarbital use for alcohol withdrawal syndrome is increasing, but its effectiveness and safety have largely been compared with lorazepam rather than against more pharmacokinetically similar long-acting, self-tapering benzodiazepines such as diazepam.
OBJECTIVE: To emulate a clinical trial comparing patients randomized to phenobarbital vs diazepam for alcohol withdrawal syndrome.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter comparative effectiveness research study analyzed data from the Premier Healthcare Database (October 2022 to August 2024), representing 754 US acute care hospitals. Adult inpatients with a primary diagnosis of alcohol withdrawal syndrome present on admission who initiated phenobarbital or diazepam on the day of hospital admission were included.
EXPOSURES: Initiation of phenobarbital or diazepam on the day of hospital admission.
MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome was hospital length of stay in days. The primary safety outcome was invasive mechanical ventilation use. Secondary outcomes assessed treatment escalation, complications of severe alcohol withdrawal syndrome, and resource utilization. Targeted maximum likelihood estimation with ensemble machine learning was used to estimate marginal mean differences and risk differences between exposure groups.
RESULTS: Among 24 643 patients (median [IQR] age, 45 [35-56] years; 18 511 male [75.1%]), 11 919 (48.4%) received phenobarbital and 12 724 (51.6%) received diazepam on the day of admission. There were no differences in hospital length of stay (marginal mean, 4.1 vs 4.3 days; marginal mean difference, -0.21 [95% CI, -0.42 to 0.00] days) or invasive mechanical ventilation use (marginal risk, 3.1% vs 2.7%; marginal risk difference, 0.4% [95% CI, -0.7% to 1.4%]) between initiation of phenobarbital vs diazepam. Secondary outcomes were also not different between phenobarbital and diazepam, except for self-directed discharge, which was more frequent among those initiated on diazepam (marginal risk, 9.5% vs 12.6%; marginal risk difference, -3.1% [95% CI, -4.9% to -1.3%]).
CONCLUSIONS AND RELEVANCE: In this multicenter study of patients hospitalized for alcohol withdrawal syndrome, there were no differences in hospital length of stay or the need for invasive mechanical ventilation between initiation of phenobarbital vs diazepam. These results may suggest near therapeutic equivalence between phenobarbital and long-acting benzodiazepines.
参考来源
- Bradley, Feeney, Law, et al. Comparative Effectiveness of Phenobarbital vs Diazepam for Alcohol Withdrawal Syndrome. JAMA Intern Med. 2026. PMID: 42862568. doi:10.1001/jamainternmed.2026.4939
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。